Table 1.

Overview of clinical studies in head and neck cancer patients with MRI before radiotherapy (pre) and at least one additional MR measurement during (mid) or post-radiotherapy (post).

Author, year	Tumor localization	N	T	MR Sequence	OAR	MRI
						pre	mid	post
Marzi, 2018 [8]	OP	40	1.5	IVIM, DCE	SG	x	x	x
Zhou, 2018 [9]	NP	28 (19)*	3.0	T2mapping, mDIXON Quant	SG	x	x	x
Zhang, 2018 [10]	NP	26	3.0	DWI	SG	x	x	x
Meheissen, 2018 [11]	OP	46	3.0	T1, T2, T1c	MS	x	x	x
Zhou, 2017 [12]	NP	26	3.0	T1rho	SG	x	x	x
Loimu, 2017 [13]	OP, L	20	1.5	DWI	SG	x		x
Hatakeyama, 2017 [14]	OP	39	1.5/3.0	T1, T2	Bone	x		x
Messer, 2016 [15]	NP	72	1.5	T1, T2	MS	x		x
Sandulache, 2016 [16]	OP	32	3.0	DCE	Bone	x	x	x
Marzi, 2015 [17]	OP, NP, HP, L	34	1.5	IVIM	SG	x	x	x
Juan, 2015 [18]	NP	11	1.5	DWI	SG	x		x
Doornaert, 2014 [19]	OP, HP	8	1.5	DWI	SG	x	x	x
Zhang, 2013 [20]	NP	28	3.0	DWI	SG
Ou, 2013 [21]	NP	14	3.0	MR sialography	SG	x		x
Cheng, 2013 [22]	NP	16	1.5	DCE	SG	x		x
Houweling, 2011 [23]	OP	18	3.0	T1, T2, DCE	SG	x		x
Lee, 2011 [24]	NP	21	1.5	DCE	SG	x		x
Kan, 2010 [25]	OP, NP, HP, L, PS, UP	14	1.5	T2	SG	x	x	x
Popovtzer, 2009 [26]	OP, NP, HP, UP	12	3.0	T1, T2	MS	x		x
Dirix, 2008 [27]	OP, OC, UP	8	1.5	DWI	SG	x		x
Astreinidou, 2007 [28]	OP, NP	9	1.5	MR sialography	SG	x	(x)	(x)

^*28 patients with repetitive T2, 18 patients with repetitive DIXON. DCE: dynamic contrast enhanced imaging, DWI: diffusion weighted imaging, HP: hypopharynx, IVIM: intravoxel incoherent motion imaging, L: larynx, MS: musculoskeletal, NP: nasopharynx, OAR: organ at risk, OC: oral cavity, OP: oropharynx, PS: paranasal sinus, SG: salivary gland, T: magnetic field strength in Tesla, T1c: T1 post contrast, UP: unknown primary.